Personalized medicine in psychiatry: problems and promises

被引:173
|
作者
Ozomaro, Uzoezi [1 ]
Wahlestedt, Claes [1 ,2 ,3 ]
Nemeroff, Charles B. [1 ,2 ,3 ]
机构
[1] Univ Miami, Leonard M Miller Sch Med, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Hussman Inst Human Genom, Ctr Therapeut Innovat, Miami, FL 33136 USA
[3] Univ Miami, Leonard M Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL USA
来源
BMC MEDICINE | 2013年 / 11卷
基金
美国医疗保健研究与质量局; 美国国家卫生研究院;
关键词
Major depressive disorder; Schizophrenia; Personalized medicine; Psychiatric hereditability; Epigenetics; Environmental factors; Endophenotypes; Pharmacogenomics; Neuroimaging genetics; CORTICOTROPIN-RELEASING-FACTOR; SEROTONIN TRANSPORTER GENE; GENOME-WIDE ASSOCIATION; INDUCED WEIGHT-GAIN; SINGLE NUCLEOTIDE POLYMORPHISM; MAJOR DEPRESSIVE DISORDER; FAMILY-BASED ASSOCIATION; 5-HT2A RECEPTOR GENE; CLOZAPINE-INDUCED AGRANULOCYTOSIS; ABNORMAL INVOLUNTARY MOVEMENTS;
D O I
10.1186/1741-7015-11-132
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The central theme of personalized medicine is the premise that an individual's unique physiologic characteristics play a significant role in both disease vulnerability and in response to specific therapies. The major goals of personalized medicine are therefore to predict an individual's susceptibility to developing an illness, achieve accurate diagnosis, and optimize the most efficient and favorable response to treatment. The goal of achieving personalized medicine in psychiatry is a laudable one, because its attainment should be associated with a marked reduction in morbidity and mortality. In this review, we summarize an illustrative selection of studies that are laying the foundation towards personalizing medicine in major depressive disorder, bipolar disorder, and schizophrenia. In addition, we present emerging applications that are likely to advance personalized medicine in psychiatry, with an emphasis on novel biomarkers and neuroimaging.
引用
收藏
页数:35
相关论文
共 50 条
  • [31] Genetics and Personalized Medicine in Antidepressant Treatment
    Gvozdic, Katarina
    Brandl, Eva J.
    Taylor, Danielle L.
    Mueller, Daniel J.
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (36) : 5853 - 5878
  • [32] Cannabis Pharmacogenomics: A Path to Personalized Medicine
    Babayeva, Mariana
    Loewy, Zvi G.
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2023, 45 (04) : 3479 - 3514
  • [33] Personalized Medicine in the Paediatric Population: The Balance Between Pharmacogenetic Progress and Bioethics
    Schiavone, Stefania
    Neri, Margherita
    Pomara, Cristoforo
    Riezzo, Irene
    Trabace, Luigia
    Turillazzi, Emanuela
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2017, 18 (03) : 253 - 262
  • [34] Coriell Personalized Medicine Collaborative®: a prospective study of the utility of personalized medicine
    Keller, Margaret A.
    Gordon, Erynn S.
    Stack, Catharine B.
    Gharani, Neda
    Sill, Courtney J.
    Schmidlen, Tara J.
    Mintzer, Joseph
    Pallies, John
    Gerry, Norman P.
    Christman, Michael F.
    PERSONALIZED MEDICINE, 2010, 7 (03) : 301 - 317
  • [35] Personalized medicine in Brazil: a new paradigm, old problems
    Pavani, Claudia
    Plonski, Guilherme Ary
    INNOVATION & MANAGEMENT REVIEW, 2021, 18 (04) : 365 - 381
  • [36] Pharmacogenomics of schizophrenia: Towards personalized psychiatry
    Gurwitz, D
    DRUG DEVELOPMENT RESEARCH, 2003, 60 (02) : 71 - 74
  • [37] Personalized Medicine: A New Normal for Therapeutic Success
    Sarvan, M. S.
    Nori, Lakshmi Prasanthi
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 83 (03) : 416 - 429
  • [38] The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
    Laing, Rachel E.
    Hess, Patricia
    Shen, Yingjie
    Wang, Jian
    Hu, Sean X.
    CURRENT DRUG METABOLISM, 2011, 12 (05) : 460 - 486
  • [39] Pharmacogenomics and Personalized Medicine
    Cecchin, Erika
    Stocco, Gabriele
    GENES, 2020, 11 (06) : 1 - 5
  • [40] Personalized medicine in rheumatology
    Szekanecz, Zoltan
    ORVOSI HETILAP, 2013, 154 (13) : 483 - 496